Clinical Trial Update: A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer [Phase 1]

View source ↗

Summary

This is a completed Phase 1 trial evaluating a combination of everolimus (RAD001), cetuximab, and irinotecan as second-line therapy for metastatic colorectal ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Everolimus (RAD001) (everolimus)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Colorectal Cancer, Colorectal Carcinoma | Phase 1 | Status: COMPLETED